Liquidia Corporation Common Stock (LQDA) Stock Price

LQDAStock

$34.35+48.19%52W

Market Cap$3.07B

P/E—

PEG Ratio—

Div yield—

Beta0.49

LQDA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-21.17%

Price vs S&P 500 (4W)-46.97%

VGM Score64.95

Book Value / Share (Quarterly)$2.19

P/TBV (Annual)13.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)114.96%

Cash Flow / Share (Quarterly)$1.66

Price vs S&P 500 (YTD)-12.33%

Gross Margin (TTM)92.56%

Net Profit Margin (TTM)30.74%

EPS (TTM)$1.39

10-Day Avg Trading Volume7.39M

EPS Excl Extra (TTM)$1.39

Revenue Growth (5Y)192.46%

EPS (Annual)$-0.80

ROI (Annual)-66.82%

Gross Margin (Annual)91.76%

Net Profit Margin (5Y Avg)-387.10%

Cash / Share (Quarterly)$3.19

P/E Basic Excl Extra (TTM)22.18x

Revenue Growth QoQ (YoY)1842.73%

ROA (Last FY)-55.78%

Revenue Growth TTM (YoY)2233.65%

EBITD / Share (TTM)$1.80

ROE (5Y Avg)-103.21%

Operating Margin (TTM)37.39%

Cash Flow / Share (Annual)$-1.20

P/B Ratio15.76x

P/B Ratio (Quarterly)36.34x

Net Income / Employee (Annual)$-319,100

EV / Revenue (TTM)6.58x

Net Interest Coverage (TTM)-2.93x

ROA (TTM)36.30%

EV / EBITDA (TTM)17.55x

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)4.40x

Quick Ratio (Quarterly)2.07x

3-Month Avg Trading Volume2.86M

52-Week Price Return48.19%

P/E Incl Extra (TTM)22.18x

Revenue / Employee (TTM)$2,087,500

Tangible BV / Share (Quarterly)$2.16

P/S Ratio (Annual)19.42x

Asset Turnover (Annual)0.06x

52-Week High$93.61

Operating Margin (5Y Avg)-368.89%

EPS Excl Extra (Annual)$-0.80

CapEx CAGR (5Y)53.23%

26-Week Price Return-11.26%

Quick Ratio (Annual)4.26x

13-Week Price Return-57.03%

Total Debt / Equity (Annual)1.49x

Current Ratio (Quarterly)2.31x

Enterprise Value$2.97B

Revenue / Share Growth (5Y)142.81%

Asset Turnover (TTM)1.18x

Book Value / Share Growth (5Y)-6.05%

Revenue / Employee (Annual)$733,000

Pretax Margin (Annual)-43.53%

Cash / Share (Annual)$2.07

3-Month Return Std Dev137.81%

Gross Margin (5Y Avg)79.13%

Net Income / Employee (TTM)$641,700

ROE (Last FY)-166.61%

Net Interest Coverage (Annual)8.84x

EPS Basic Excl Extra (Annual)$-0.80

Receivables Turnover (TTM)7.61x

EV / Free Cash Flow (TTM)20.09x

Total Debt / Equity (Quarterly)0.90x

EPS Incl Extra (TTM)$1.39

Receivables Turnover (Annual)3.86x

ROI (TTM)50.02%

P/S Ratio (TTM)6.82x

Pretax Margin (5Y Avg)-387.10%

Revenue / Share (Annual)$1.84

Tangible BV / Share (Annual)$0.87

Forward P/E14.34x

Price vs S&P 500 (52W)32.66%

P/E Ratio (TTM)22.18x

Year-to-Date Return-0.41%

5-Day Price Return24.14%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-50.21%

Net Profit Margin (Annual)-43.53%

Month-to-Date Return13.52%

Cash Flow / Share (TTM)$-0.86

EBITD / Share (Annual)$-0.60

Operating Margin (Annual)-32.45%

LT Debt / Equity (Annual)0.92x

P/CF (TTM)18.33x

ROI (5Y Avg)-61.19%

P/E Excl Extra (TTM)22.18x

LT Debt / Equity (Quarterly)0.63x

EPS Basic Excl Extra (TTM)$1.39

P/TBV (Quarterly)36.88x

P/B Ratio (Annual)12.93x

Inventory Turnover (TTM)1.57x

Pretax Margin (TTM)33.16%

Book Value / Share (Annual)$0.91

Price vs S&P 500 (13W)-59.72%

Beta0.49x

Revenue / Share (TTM)$4.45

ROE (TTM)149.64%

52-Week Low$21.94

vGradeD

gGradeA

mGradeC

vgmGradeB

LQDA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	$0.85	$0.74	-13.20%(-$0.11)
Q1 2026	May 11, 2026	$0.40	$0.52	+29.19%(+$0.12)
Q4 2025	Mar 5, 2026	$0.33	$0.15	-55.09%(-$0.18)
Q3 2025	Nov 3, 2025	-$0.35	-$0.04	+88.65%(+$0.31)
Q2 2025	Aug 12, 2025	-$0.39	-$0.49	-24.84%(-$0.10)

LQDA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.36

4.21

4.13

4.07

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LQDALiquidia Corporation Common Stock	D	A	C	6.8x	2233.7%	92.6%	—	$34.35
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Liquidia Corporation Common Stock

Liquidia Corp is a biopharmaceutical company focused on pulmonary hypertension and related lung diseases. The company leverages proprietary PRINT technology to engineer uniform drug particles, enabling its lead product YUTREPIA (treprostinil) inhalation powder, while also generating revenue from Treprostinil Injection sales.

LQDA Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.98

Revenue estimate$214.15M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

LQDA Insider Transactions

SellOct 12, 2026
JEFFS ROGER A
Chief Executive Officer
Shares: 32,744Value: $932,549
SellOct 12, 2026
KASETA MICHAEL
Chief Operating Officer
Shares: 18,938Value: $539,354
SellOct 12, 2026
SCHUNDLER RUSSELL
General Counsel
Shares: 13,692Value: $389,948
SellOct 12, 2026
SAGGAR RAJEEV
Officer
Shares: 9,218Value: $262,529
SellOct 12, 2026
MOOMAW SCOTT
Officer
Shares: 8,863Value: $252,418

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

AVNTAvient CorporationPlastics & Resins
RLAYRelay Therapeutics, Inc. Common StockBiological Products
TARSTarsus Pharmaceuticals, Inc. Common StockBiological Products
SMGThe Scotts Miracle-Gro CompanyAgricultural Chemicals
COTYCOTY INCCosmetics & Toiletries
DNLIDenali Therapeutics Inc. Common StockBiological Products
FULH.B. Fuller CompanyAdhesives & Sealants
WDFCWd-40 CoIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$21.94

High$93.61